Loading
TScan Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 23 Dec 2025.
TScan Therapeutics, Inc.: what insiders have been doing
TScan Therapeutics, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for TScan Therapeutics, Inc. logged 3 filings by 3 insiders.
Every open-market trade in the period is a purchase: 1 purchase worth €61k, from 1 insider, and not a single sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. At €61k, the purchase published on 23 December 2025 by Lynx1 Capital Management LP is the largest of the period.
The clock since the last published purchase (23 December 2025) now reads 299 days. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade.
For context, the typical company on the same exchange (median of 5,810 companies) published 19 filings over the same period, against 3 filings here. The full history, which starts in 2021, counts 21 purchases against 1 sale.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
28
Thresholds
n/a
Buy Volume
€4M
21 ops. · all time
Sell Volume
€23,513
1 ops. · all time
Who traded when
BuySaleLynx1 Capital Management LP4 buys
Since the insiders bought
- -1.0%Entry US$1.04 · Close at T+90 US$1.03
- +11.9%Entry US$2.85 · Close at T+365 US$3.19
- +61.8%Entry US$2.49 · Close at T+365 US$4.03
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.21
Analyst consensus
2 analysts2.60/5
US$1.00Target US$1.00(+375%)US$1.00
Income statement
RevenueUS$10.3M
EBITDA-US$124.1M-1202% margin
Net income-US$129.8M-1256.8% margin
Valuation
PER (forward)-0.4x
P/Book0.2x
Beta1.14
Balance sheet & cash
Market capUS$13.8M
Total debtUS$94.1M
Free Cash Flow-US$139.7M
Debt / Equity132%
Profitability & ownership
ROE-95.8%
ROA-31.5%
% insiders1.8%
% institutions67.9%
Last declaration on 2 October 2026
Declarations28 total
300,000 shares0Voting Common StockSEC:0001193125-26-412518:0
1,000,000 shares0Voting Common StockSEC:0001193125-26-412521:0
80,069 shares@ US$0.89893.7% of flowCommon stock, $0.0001 par value per share ("Common Stock")SEC:0000902664-25-005396:0
Canonical exit: 19 Mar 2026 (T+90)
1,388,794 shares@ US$1.2089.2% of flowCommon stock, $0.0001 par value per share ("Common Stock")SEC:0000902664-25-002511:0
Canonical exit: 17 Aug 2025 (T+90)
31,800 shares@ US$3.00725.5% of flowCommon stock, $0.0001 par value per share ("Common Stock")SEC:0000902664-24-006934:0
Canonical exit: 12 Mar 2025 (T+90)
947 shares@ US$4.34420.2% of flowCommon stock, $0.0001 par value per shareSEC:0000902664-24-006718:0
Canonical exit: 13 Feb 2025 (T+90)
5,000 shares@ US$5.2932.7% of flowVoting Common StockSEC:0000950170-24-109133:0
Canonical exit: 22 Dec 2024 (T+90)
5,000 shares@ US$5.6935.2% of flowVoting Common StockSEC:0000950170-24-101166:0
Canonical exit: 21 Nov 2024 (T+90)
54,895 shares@ US$4.8588.9% of flowVoting Common StockSEC:0000950170-24-101161:0
28,830 shares@ US$4.886658.3% of flowVoting Common StockSEC:0000950170-23-072291:0
Canonical exit: 17 Mar 2024 (T+90)
5,000 shares@ US$5.0832.1% of flowVoting Common StockSEC:0000950170-23-071208:0
Canonical exit: 13 Mar 2024 (T+90)
37,880 shares@ US$2.628441.7% of flowVoting Common StockSEC:0000899243-23-014618:0
Canonical exit: 31 Aug 2023 (T+90)
10,000 shares@ US$2.51481.4% of flowCommon stock, $0.0001 par value per share Common StockSEC:0000902664-23-003407:0
2,842 shares@ US$1.50473.0% of flowVoting Common StockSEC:0000899243-22-039506:0
Canonical exit: 27 Mar 2023 (T+90)
15,000 shares@ US$3.622623.8% of flowVoting Common StockSEC:0000899243-22-019018:0
Canonical exit: 16 Aug 2022 (T+90)
40,800 shares@ US$1.704.7% of flowCommon StockSEC:0001209191-22-028579:0
Canonical exit: 8 Aug 2022 (T+90)
15,000 shares@ US$3.398835.0% of flowVoting Common StockSEC:0000899243-22-012476:0
Canonical exit: 22 Jun 2022 (T+90)
48,670 shares@ US$1.9738.9% of flowVoting Common StockSEC:0000899243-21-049764:0
4,716 shares@ US$7.475711.1% of flowVoting Common StockSEC:0000899243-21-037802:0
Canonical exit: 22 Dec 2021 (T+90)
4,943 shares@ US$6.2197100.0% of flowVoting Common StockSEC:0000899243-21-037147:0
Canonical exit: 19 Dec 2021 (T+90)
5,000 shares@ US$6.31720.4% of flowVoting Common StockSEC:0000899243-21-037149:0
Canonical exit: 20 Dec 2021 (T+90)
5,885 shares@ US$8.483531.9% of flowVoting Common StockSEC:0000899243-21-035684:0
Canonical exit: 8 Dec 2021 (T+90)
11,000 shares@ US$8.733337.3% of flowVoting Common StockSEC:0000899243-21-035442:0
Canonical exit: 7 Dec 2021 (T+90)
2,500 shares@ US$9.0832100.0% of flowVoting Common StockSEC:0000899243-21-034610:0
Canonical exit: 25 Nov 2021 (T+90)
104,698 shares@ US$15.0095.3% of flowCommon StockSEC:0001638599-21-000606:0
Canonical exit: 18 Oct 2021 (T+90)
25 of 28 declarations
About TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a U.S.-based biotechnology company listed on the NASDAQ market in the United States. The company was created to pursue a more precise form of cancer immunotherapy through T cell receptor-engineered T cell, or TCR-T, therapies. Its operational headquarters are in Waltham, Massachusetts, a major biotech cluster in the Boston area. For investors, TScan is best viewed as a clinical-stage oncology platform company: it has meaningful scientific optionality, but it also carries the execution, funding, and regulatory risks typical of early- to mid-stage cell therapy developers.
TScan’s core business is centered on a proprietary discovery platform that identifies naturally occurring T-cell receptors capable of recognizing tumor-associated antigens in the context of specific HLA types. That platform underpins a pipeline spanning both hematologic malignancies and solid tumors. In hematologic cancers, the company is advancing donor-derived, allogeneic TCR-T candidates designed to reduce residual disease and prevent relapse around hematopoietic cell transplantation. In solid tumors, TScan is building a broader ImmunoBank and a multiplex treatment concept under the T-Plex framework, aiming to administer up to three TCR-T product candidates simultaneously based on the patient’s tumor targets and HLA profile.
Read moreShow less
A notable competitive feature is TScan’s internal GMP manufacturing capability in Waltham. In a field where manufacturing complexity can slow development and inflate costs, owning part of the production infrastructure is strategically important. It supports faster iteration across programs and may help the company scale clinical supply more efficiently than peers that rely entirely on external manufacturing partners. The company also emphasizes its non-viral engineering approach and the expansion of HLA coverage, both of which are intended to widen patient eligibility and strengthen the clinical relevance of its pipeline.
From a market-position standpoint, TScan operates in a highly competitive segment of cell therapy and oncology, where differentiation depends on clinical data, translational biology, and manufacturability. The company is still pre-commercial and therefore not yet supported by product sales; its near-term value drivers are clinical milestones, regulatory filings, and cash runway. In its most recent public updates in 2025 and early 2026, TScan highlighted strategic prioritization of its heme program, FDA clearance of IND applications for TSC-102-A01 and TSC-102-A03, and updated clinical data presentations. The company also stated that its cash resources are expected to fund operations into the second half of 2027, which is an important benchmark for a development-stage biotech. Overall, TScan combines a differentiated science platform with substantial binary-event exposure, making it a high-risk, high-upside name for public equity investors.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
